In 2019, the Bladder Cancer Molecular Taxonomy Group (BCMTG) presented a consensus molecular classification comprising six subtypes of muscle-invasive bladder cancer (MIBC). The non-luminal subtypes were the most consistent with previous models. Subsequent studies in 2019 have revealed molecular heterogeneity among the luminal subtypes and their possible clinical ramifications.
Key advances
In 2019, the Bladder Cancer Molecular Taxonomy Group put substantial effort into providing a consensus molecular classification comprising six subtypes of muscle-invasive bladder cancer (MIBC).
The consensus classifier contains three luminal subtypes.
In 2019, three studies were published in which the luminal subtype could be subdivided further by either immunohistochemistry, long non-coding RNA expression or pathological upstaging.
Moreover, tumour samples with variant histology (nested or micropapillary) fall into the luminal subgroup but have an aggressive disease course.
Consequently, future subtyping studies should reveal which classification approach is the best for clinical decision-making.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. https://doi.org/10.1016/j.eururo.2019.09.006 (2019).
Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540–556 (2017).
Sjodahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377–3386 (2012).
Bernardo, C. et al. Molecular pathology of the luminal class of urothelial tumors. J. Pathol. 249, 308–318 (2019).
Seiler, R. et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur. Urol. 72, 544–554 (2017).
Lotan, Y. et al. Molecular subtyping of clinically localized urothelial carcinoma reveals lower rates of pathological upstaging at radical cystectomy among luminal tumors. Eur. Urol. 76, 200–206 (2019).
Gibb, E. A., Brown, C. J. & Lam, W. L. The functional role of long non-coding RNA in human carcinomas. Mol. Cancer 10, 38 (2011).
de Jong, J. J. et al. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. Genome Med. 11, 60 (2019).
Guo, C. C. et al. Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer. Eur. Urol. 70, 611–620 (2016).
Weyerer, V. et al. Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma. Histopathology https://doi.org/10.1111/his.13958 (2019).
Acknowledgements
The authors thank J. L. Boormans for helpful suggestions on the manuscript and E. A. Gibb for helpful suggestions on the manuscript and personal communication.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
de Jong, J.J., Zwarthoff, E.C. Molecular and clinical heterogeneity within the luminal subtype. Nat Rev Urol 17, 69–70 (2020). https://doi.org/10.1038/s41585-019-0262-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0262-7
This article is cited by
-
Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis
British Journal of Cancer (2022)
